May increase the risk of infection. Evaluate for TB prior to initiating treatment with risankizumab.
Risankizumab-Rzaa is a biosimilar to Risankizumab.
- TRADE NAME: Skyrizi (AbbVie)
- INDICATIONS: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
- CLASS: Interleukin-17 (IL-17) antagonist / interleukin-17 inhibitor, Interleukin-23 inhibitor, Monoclonal antibody
- HALF-LIFE: ~ 28 days
- FDA APPROVAL DATE: 04/23/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Live vaccines - PREGNANCY: Limited available data in pregnant women to evaluate a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome. Risankizumab may be transmitted from the mother to the developing fetus.
- See adverse reactions attributed to class:
Interleukin-17 (IL-17) antagonist / interleukin-17 inhibitor
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of risankizumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 05/26/2025
